The challenges posed by the immune response is one of the biggest obstacles to developing safe, effective, and durable gene therapies. Over the last two decades, drug developers have observed and begun developing solutions to a wide range of immune responses to AAV vectors. The 4th Annual Gene Therapy Immunogenicity Summit is your opportunity to connect with like-minded peers from gene therapy drug developers, along with leading academics, regulators, and key service providers, all making strides with improving risk assessments, monitoring, and mitigating against AAV gene therapy immunogenicity.

Registering for 2023 will grant you access to keynote plenaries from leading gene therapy figures, deep-dive discussions into pressing preclinical and clinical developments, and highly appraised networking opportunities with 150+ of your peers, all to leave you with the actionable tools, insights, and connections you need to enhance your immunogenicity-focused work.

Read on immunogenicity.com

Continue reading at genetherapy-immunogenicity.com

Health and Wellness

Facebook Share

Twitter Share

Linkedin Share

Email Share